Integrated Diagnostics Holdings (LSE:IDHC) reported a robust performance for 2025, with revenues rising 37% to EGP 7.9 billion. Growth was driven by an 11% increase in test volumes alongside a 24% improvement in average revenue per test, reflecting both higher demand and pricing dynamics.
The group significantly expanded its footprint, increasing its branch network from 628 to 767 locations, primarily across Egypt. Demand remained resilient despite pricing adjustments, while operations in Sudan continued to be largely paused due to ongoing conflict.
Profitability strengthened notably, with gross profit up 54% and EBITDA climbing 61%, resulting in improved margins. These gains were supported by tighter cost management, procurement efficiencies, and disciplined control of selling, general, and administrative expenses. Net profit rose 29%, while adjusted net profit surged 79%, highlighting the strength of underlying earnings.
The board declared a modest dividend, balancing shareholder returns with the need to retain capital for further growth. Strategic expansion remains a priority, including the acquisition and integration of Cairo Ray for Radiotherapy, which enhances the company’s capabilities in delivering a more comprehensive diagnostics offering.
More about Integrated Diagnostics Holdings
Integrated Diagnostics Holdings is a major provider of diagnostic healthcare services across the Middle East and Africa, with operations in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The company offers a broad range of services including laboratory testing, radiology, and radiotherapy, serving both individual patients and corporate clients in rapidly growing healthcare markets.
Leave a Reply